Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Oruka Therapeutics is scheduled to participate in the Morgan Stanley Global Healthcare Conference, which may serve as a near-term catalyst for investor sentiment and stock volatility.
Oruka Therapeutics will attend the 2026 Morgan Stanley Global Healthcare Conference in New York from September 14-16, 2026. Management's participation and potential commentary on the clinical progress of ORKA-001 and ORKA-002 may influence investor sentiment and short-term stock price movement.
GlobeNewswire